NCX 320

23
Ibuprofen 24 a b s t r a c t A resolutive therapy for muscular dystrophies, a heterogeneous group of genetic diseases leading to muscular degeneration and in the severe forms to death, is still lacking. Since inflammation and defects in nitric oxide generation are recognized key pathogenic events in muscular dystrophy, we have analysed the effects of a derivative of ibuprofen, NCX 320, belonging to the class of cyclooxygenase inhibiting nitric oxide donator (CINOD), in the ␣-sarcoglycan null mice, a severe mouse model of dystrophy. NCX 320 was administered daily in the diet for 8 months starting 1 month from weaning. Muscle functional recovery was evaluated by free wheel and treadmill tests at 8 months. Serum creatine kinase activity, as well as the number of diaphragm inflammatory infiltrates and necrotic fibres, was measured as indexes of skeletal muscle damage. Muscle regeneration was evaluated in diaphragm and tibialis anterior muscles, measuring the numbers of centronucleated fibres and of myogenic precursor cells. NCX 320 mitigated muscle damage, reducing significantly serum creatine kinase activity, the number of necrotic fibres and inflammatory infiltrates. Moreover, NCX 320 stimulated muscle regeneration increasing significantly the number of myogenic precursor cells and regenerating fibres. All these effects concurred in inducing a significant improvement of muscle function, as assessed by both free wheel and treadmill tests. These results describe the properties of a new compound incorporating nitric oxide donation together with anti-inflammatory properties, showing that it is effective in slowing muscle dystrophy progression long term. Of importance, this new compound deserves specific attention for its potential in the therapy of muscular dystrophy given that ibuprofen is well tolerated in paediatric patients and with a profile of safety that makes it suitable for chronic treatment such as the one required in muscular dystrophies.
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Introduction
25
Nitric oxide (NO) is involved in many mechanisms responsi-
26
ble for preserving muscle function [1] including both pre-synaptic
27
Abbreviations: NO, nitric oxide; DMD, Duchenne muscular dystrophy; NCX 320, 4-(nitrooxy)butyl 2-(4-isobutylphenyl)propanoate; CINOD, cyclooxygenase inhibiting nitric oxide donator; nNOS, neuronal nitric oxide synthase; LPS, lipopolysaccharide from Escherichia coli; PGE2, prostaglandin E2; IFN␥, interferon-␥; COX-1, cyclooxygenase 1; COX-2, cyclooxygenase 2; ODQ, 1H- [1, 2, 4] oxadiazolo[4, 3-a] quinoxalin-1-one; cGMP, cyclic guanosine monophosphate; CK, creatine kinase; ␣-SG, ␣-sarcoglycan; mdx, muscle dystrophin-deficient mice.
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130
After equilibration, aortic segments were pre-contracted submax- ( Fig. 3A and B) .
283
To investigate the mechanism of this effect, we analysed skeletal by blue in the Masson trichrome staining (Fig. 4D) . On the contrary,
299
ibuprofen failed to significantly reduce necrotic fibres at 8 months 300 of age in diaphragm muscles (Fig. 4B) .
301
In addition, animals treated with NCX 320 showed a reduced 302 inflammatory reaction compared to the control group as judged by 
317
We analysed sections of muscles isolated from mice after with NCX 320 with respect to control ␣-SG null mice while ibupro-323 fen treatment was ineffective (Fig. 6A ).
324
We also isolated the myogenic precursor cells from these Fig. 6C and D) . 
Discussion
334
The pharmacological approaches to human muscular dystro- some cases target only subsets of patients [39, 40] .
350
In this study, we have characterised NCX 320, a member of [18]. However, flurbiprofen produces severe gastrointestinal dam-378 age which makes it unsuitable for long-term treatment, especially 379 in paediatric patients [46] . Therefore, we have focused on NCX 320 380 because it is based on ibuprofen, whose profile of safety and tolera-381 bility is well established and consequently is accepted for paediatric 382 use [47] . NCX 320 is indeed cleaved to its active metabolites ibupro- 
396
It is also important to note that the drug was administered 397 starting from weaning until 10 months of age thus initiating when 398 animals show the first clear signs of pathology [49] . 
